Global chemotherapy-induced thrombocytopenia Market - 2023-2030

Global chemotherapy-induced thrombocytopenia Market - 2023-2030

The global chemotherapy-induced thrombocytopenia market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX% during the forecast period 2023-2030.

Chemotherapy-induced thrombocytopenia (CIT) is characterized by a decreased platelet count in the blood as a result of chemotherapy treatment. Because platelets are necessary for blood clotting, a drop in their number can cause issues including increased bleeding. Nowadays, cancer patients have higher survival rates because of improvements in chemotherapy methods and schedules. However, this has also increased the prevalence of CIT, necessitating the use of potent therapies.

The need for therapies has increased as a result of early detection and treatment of CIT and its potential complications by healthcare professionals and patients. The number of available treatments for CIT has increased as a result of pharmaceutical companies' investment in research and development to provide novel therapies and medications.

Market Dynamics: Drivers

The growing cancer incidence

Cancer is a leading cause of death globally. In 2022, there were 2.74 million new cases of cancer, an increase of 2.3% from 2020. Similar to this, figures from the European Commission published in the European Cancer Information System show a 2.4% increase in cancer mortality from 2020. If incidence stays unchanged and population growth and aging follow previous trends, it is anticipated that there will be 28 million new cancer cases globally each year by 2040.

It is projected that the UK's incidence rate for all malignancies combined (excluding non-melanoma skin cancer) is greater than that of most of the European nations. Female breast, bowel (including anus), prostate, and lung cancer are the four most prevalent cancers in the UK and in all of Europe.

According to estimates, the UK has a higher incidence rate of all malignancies than the majority of other nations in the world, with the exception of non-melanoma skin cancer. The four most prevalent cancer kinds worldwide are the same as those in the UK. As cancer rates rise, more individuals undergo chemotherapy, increasing the likelihood of CIT.

Limited treatment options

There are few effective therapy for CIT, and not all patients respond favorably to them. This lack of therapeutic alternatives might make it difficult to manage CIT well, which can cause consequences. Research and development expenses for new CIT medications or treatments are high. Investment in CIT research may be discouraged by the expense of carrying out clinical trials, gaining regulatory licenses, and bringing a new treatment to market.

Segment Analysis

The global chemotherapy-induced thrombocytopenia market is segmented based on drug class, end-user and region.

The thrombopoietin receptor agonists segment accounted for approximately 34.5% of the market share

According to journal of clinical medicine in 2021, Eltrombopag and romiplostim are examples of thrombopoetin receptor agonists (TPO-RAs), which interact with the thrombopoietin receptor on megakaryocytes to stimulate platelet production. Eltrombopag is a small molecule TPO receptor stimulator, whereas romiplostim is a peptibody (i.e., a fusion of a new peptide and antibody).

Eltrombopag or romiplostim binding to the transmembrane region of the receptor or to the distal domain of the thrombopoietin receptor, respectively, activates a number of signal transduction pathways, including the JAK-STAT signaling pathway, which promotes the proliferation and differentiation of megakaryocytes.

Eltrombopag has a license for the treatment of thrombocytopenia and aplastic anemia in hepatitis C patients receiving interferon-based therapy. The only therapy for CIT that has been licensed in the US is recombinant IL-11 (oprelvekin). However, because of the negative effects, its use is relatively restricted.

Geographical Analysis

North America accounted for approximately 41.7% of the market share in 2022

North America has been a dominant force in the chemotherapy-induced thrombocytopenia market. Cancer is the second most common cause of death in the United States and a major global public health issue. Using incidence data from central cancer registries and mortality data from the National Center for Health Statistics, the American Cancer Society estimates the number of new cancer cases and deaths in the United States each year and compiles the most recent information on population-based cancer occurrence and outcomes. The United States is expected to see 1,958,310 new cancer cases and 609,820 cancer-related deaths in 2023.

According to European Journal of Heamatology, in 2021, cancer type and chemotherapy regimen have a significant impact on the incidence and prevalence of chemotherapy-induced thrombocytopenia (CIT), which ranges from 16% in head and neck cancer to 68% in hematologic cancers, from 8% in taxane-based regimens to 37% in gemcitabine-based regimens, and from 82% in carboplatin monotherapy. The largest risk of thrombocytopenia has consistently been linked to platinum- and gemcitabine-based regimens. Patients with colorectal cancer had the highest prevalence of thrombocytopenia in solid tumor patients, followed by those with non-small cell lung cancer and ovarian cancer. Hence, the rising prevalence of cancer and chemotherapy-induced thrombocytopenia drives the market in the region.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global chemotherapy-induced thrombocytopenia market. The pandemic has had an impact on clinical trials for CIT medicines and treatments. The development and approval of novel medicines were delayed as numerous trials were postponed or stopped.

Some cancer treatment methods were changed during the pandemic to cut down on the number of hospital visits or to give priority to procedures that posed less of a risk to the patient's immune system. These modifications may impact the occurrence and treatment of CIT.

By Drug Class
• Thrombopoietin Receptor Agonists
• Thrombopoietic Agents
• Others

By End-User
• Hospitals
• Specialty Clinics
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Swedish Orphan Biovitrum AB, Amgen Inc, Novartis AG, Pfizer Inc., Jiangsu HengRui Medicine Co., Ltd., Mylan N.V., and others.

Key Developments
• In October 2020, Swedish Orphan Biovitrum AB declared topline findings from a phase 3 study of the oral thrombopoietin (TPO) receptor agonist avatrombopag in solid tumor cancer patients with chemotherapy-induced thrombocytopenia (CIT). Despite the fact that avatrombopag boosted platelet counts in comparison to placebo as was expected, the study's composite primary goal of preventing platelet transfusions, chemotherapy dose reductions of 15% or more, and chemotherapy dose delays of four days or more was not achieved.

Why Purchase the Report?
• To visualize the global chemotherapy-induced thrombocytopenia market segmentation based on drug class, End-User, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of chemotherapy-induced thrombocytopenia market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global chemotherapy-induced thrombocytopenia market report would provide approximately 41 tables, 43 figures, and 186 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies